BioCentury
ARTICLE | Deals

ChemoCentryx attracted multiple suitors, but not until after first approval

Amgen was one of three companies interested in acquiring ChemoCentryx since April 2020

September 1, 2022 9:57 PM UTC

ChemoCentryx began its search for strategic alliances over two years before announcing its acquisition by Amgen on Aug. 4, but it wasn’t until the biotech gained its first drug approval last October that suitors came to the table, according to an SEC filing by the biotech. 

The $4 billion deal gave Amgen Inc. (NASDAQ:AMGN) Tavneos avacopan, a therapy to treat auto-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Amgen also gains CCX559, an oral PD-1 inhibitor, from the clinical pipeline...

BCIQ Company Profiles

Amgen Inc.

ChemoCentryx Inc.